Primary Cells Global Market Report 2024

The primary cells market size has grown rapidly in recent years. It will grow from $1.33 billion in 2023 to $1.49 billion in 2024 at a compound annual growth rate (CAGR) of 12.2%. The expansion witnessed in the historical period can be ascribed to several factors, including the growing prevalence of cancer, heightened investments in regenerative medicine research, increasing demand for monoclonal antibodies, the benefits offered by primary human cells compared to cell lines, and the rising incidence of chronic diseases. These factors collectively contributed to the growth and advancement of primary cell-based research and applications during this period.

The primary cells market size is expected to see rapid growth in the next few years. It will grow to $2.24 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. In the forecast period, growth is anticipated due to several factors, including the increasing demand for personalized medicine, a heightened focus on stem cell research, rising investments in the field, and the growing adoption of cell-based assays. Major trends expected in this period include an increased demand for human primary cells, advancements in research tools and technologies, and a greater adoption of cell-based therapies. These trends collectively indicate a promising outlook for the expansion and development of primary cell-related research and applications in the coming years.

The anticipated increase in government funding for cancer research is poised to drive the growth of the primary cells market in the foreseeable future. Government funding plays a crucial role in supporting various aspects of primary cell research, including project funding, personnel support, infrastructure development, training, regulatory compliance, and technological advancements. For example, in May 2022, the American Institute for Cancer Research (AICR) in the United States sought $49 billion in funding for 2023, marking a $4.1 billion increase from the previous year's allocation of $46.4 billion. This surge in funding underscores the significant role of government support in fostering advancements in cancer research, consequently fueling the growth of the primary cells market.

Leading companies in the primary cell market are directing their efforts towards enhancing cell products, particularly novel serum-free mediums, to address the challenges encountered by cell therapy developers during the manufacturing workflow, especially in allogeneic cell therapy workflows. Novel serum-free mediums, devoid of animal-derived sera such as fetal bovine serum (FBS), are critical for cell culture or tissue culture. For instance, in January 2021, Thermo Fisher Scientific Inc., a US-based biotechnology company, introduced the Gibco CTS OpTmizer Pro Serum-Free Medium (SFM), specifically tailored for the growth and expansion of human T lymphocytes utilized in allogeneic cell therapies. This medium is engineered to enhance central memory phenotype and cell growth, resulting in increased production of central memory cells within shorter durations. Moreover, it supports extended workflows, facilitates high-density cultures, and is compatible with closed systems and automation, catering to the evolving needs of cell therapy developers.

In April 2023, AnaBios Corporation, a US-based biotechnology company, completed the acquisition of Cell Systems, further expanding its diverse portfolio of human tissue and cells. This strategic acquisition aimed to enrich AnaBios' translational tools and reagents, catering to academic, pharmaceutical, and biotech researchers. By leveraging Cell Systems' expertise in providing human primary cells and cell culture media, AnaBios seeks to optimize research programs and provide enhanced human insights to advance scientific discovery and therapeutic development efforts.

Major companies operating in the primary cells market report are Thermo Fisher Scientific Inc, Merck KGaA, BD Biosciences, Corning Incorporated, Cytiva, Lonza Group Ltd, Charles River Laboratories Inc., STEMCELL Technologies Inc, American Type Culture Collection, Cell Signaling Technology, BioIVT, InvivoGen, HemaCare Corporation, Creative Bioarray Inc., PromoCell GmbH, CellGenix, AllCells LLC, Axol Bioscience Ltd, PBS Biotech Inc, AnaBios Corporation, ReachBio Research Labs, PELOBIOTECH GmbH, Cell Biologics Inc., ZenBio Inc., StemBioSys Inc.

North America was the largest region in the primary cells market in 2023. The regions covered in the primary cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the primary cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Primary cells are cells sourced directly from living tissues of animals or humans, subsequently processed to render them suitable for utilization in various cell treatments. These cells find application across a range of uses, such as 3D cell cultivation, virology, cancer research, stem cell treatment, and tissue restoration.

Primary cells encompass various types, including hematopoietic cells, dermatophytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, among others. Hematopoietic cells, for instance, are a form of stem cell responsible for generating diverse blood cell types within the body. These cells originate from both human and animal primary sources and are utilized by pharmaceuticals, biotechnology companies, contract research organizations (CROs), academic and research institutes, and other entities for various applications.

The primary cells market research report is one of a series of new reports that provides primary cells market statistics, including primary cells industry global market size, regional shares, competitors with a primary cells market share, detailed primary cells market segments, market trends and opportunities, and any further data you may need to thrive in the primary cells industry. This primary cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The primary cells market consists of revenues earned by entities by providing services such as cell isolation services, primary cell culture services, cell characterization, and authentication. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary cell market also includes sales of cell culture media and reagents, cell culture plates and flasks, cell isolation kits, and transfection reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.